European and US Guidelines

Slides:

Advertisements

Similar presentations

New-generation drug-eluting stents and dual antiplatelet therapy: overview Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies.

Advertisements

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

PRODIGY Objective Study Design Primary Composite Endpoint

M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Date of download: 7/8/2016 From: Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Stent Thrombosis and Optimal Duration of DAPT

Current Problems in Cardiology

Short versus Long DAPT Studies – An Academic View

Polypharmacy Anticoagulation: AF meets PCI

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

(p < for group 1 or 2 vs. group 3)

PCI in Patients With Diabetes: Show Me the Data

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Cardiogenic Shock.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Nat. Rev. Cardiol. doi: /nrcardio

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Terms of Use. Terms of Use.

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

AF and PCI in Practice.

TAVR and the Risk of Thrombosis

Learning Objectives Classification of VTE Goals of VTE Treatment.

Thank you for taking the pre-assessment

Real-World Evidence in VTE

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

How and why this study may change my practice ?

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

ENDEAVOR IV: 5 Year Final Outcomes

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.

Long Term Clinical Results from the Endeavor Program: 5-Year Follow up

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

Seung-Yul Lee et al. JCIN 2018;j.jcin

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Primary safety endpoint

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

DAPT Duration in PCI: The Art of Medicine When the Science Might Not Exist

European and US Guidelines

European and US Guidelines

“Optimal” DAPT Duration and DES Revascularization A Less than “Optimal” Evidence Basis

Long-Term DAPT: Bleeding Risk

PRODIGY: 2-Year Death/MI/Stroke

PRODIGY: 2-Year BARC 2, 3, or 5 Bleeding

PRODIGY: Outcomes Relative to Stent Type and DAPT Duration

PRODIGY: Outcomes Relative to Stent Type and DAPT Duration

PRODIGY: Outcomes Relative to Stent Type and DAPT Duration

REAL-LATE/ZEST-LATE: 2-Year End Points

RCT Sample Size Calculations (6 mo vs 12 mo) Delta, Event-free Duration, Time to End Point Influence (N)

DAPT Trial: Total Enrollment

Pooled Xience EES Analysis Timing of First DAPT Interruption and ST Through 1 Year

RESOLUTE Pooled DAPT Interruption Analysis Timing of First DAPT Interruption and ST Through 1 Year

RESOLUTE Pooled DAPT Interruption Analysis Timing of First DAPT Interruption and ST Through 1 Year

Global Leaders

WOEST 1-Year Outcomes: ASA/Clopidogrel/Warfarin vs Clopidogrel/Warfarin

DAPT Trial Randomization Rates

Conclusions

Conclusions (cont)

Conclusions (cont)

Conclusions (cont)

双重抗血小板治疗的合适使用时间及如何合理应用

展望

Spanish Perspective

Recommendation for 12 Months of DAPT After DES Implantation

Recommended Duration of DAPT After PCI

Discontinuation of Antiplatelet Therapy as Predictor of Stent Thrombosis

Pipeline: RCT on DAPT After Stenting

EES vs PES: 1-Year Meta-Analysis (n = 6683)

References

References (cont)

References (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)